{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Opioid-Sparing Analgesia in Postoperative Pain Management"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was total morphine consumption within 24 hours postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation and allocation concealment methods were assessed"
      },
      "Blinding": {
        "score": 2,
        "evidence": "blinding of participants and outcome assessors"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Opioid-sparing analgesia reduced total morphine consumption (mean difference [MD] = -9.47 mg, 95% confidence interval [CI] -13.00 to -5.95)"
      },
      "Harms": {
        "score": 1,
        "evidence": "The incidence of postoperative nausea and vomiting (PONV) was lower (odds ratio [OR] = 0.73, 95% CI 0.59 to 0.90), as was pruritus (OR = 0.64, 95% CI 0.41 to 0.98)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42024579882."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}